Epochal Precision Anti-Cancer Therapeutics

About Epochal Precision Anti-Cancer Therapeutics (EPAT) 

Exton Pilot Plant

EPAT focuses on oncology drug development utilizing Eisai’s unique Antibody-Drug Conjugate (ADC) technology (RESPECT®) proprietary payloads, and bispecific antibodies. 

 

An offshoot of Morphotek Inc., which was founded in 2000 and acquired by Eisai in 2007, the Exton, Pa.-based site leverages its proprietary technologies with the chemistry excellence of Eisai. EPAT works in close collaboration with Eisai’s other oncology discovery groups.